The short answer
Review melatonin before adding it to trazodone, particularly if you already feel sleepy or unsteady. A new combination-study protocol has not yet provided results that quantify the effect.
What this answer covers
Oral melatonin with immediate-release trazodone; sleep-study and product formulations are not interchangeable.
- Supplement or preparation
- Melatonin
- Medication ingredient
- trazodone
The medicine can impair alertness
Trazodone may cause drowsiness and affect thinking or coordination. Existing daytime symptoms are a reason to review another sleep product.
A planned combination trial is not a result
A 2026 protocol describes trazodone plus melatonin after traumatic brain injury and plans to measure daytime sleepiness. It does not report completed safety or benefit results.
Comparisons do not prove safe combinations
A Parkinson disease trial compared melatonin and trazodone as separate treatments. Melatonin product information also reports functional effects with imipramine, a different antidepressant; neither establishes this pair’s effect size.
Watch for impaired alertness
Trazodone can affect alertness and coordination. Avoid driving if affected and contact the prescriber if added sleepiness, confusion or unsteadiness appears after a new product. Severe confusion, fainting or inability to wake needs urgent assessment.
Evidence and practical considerations
Side effects & toxicity
Conditional alertness review, with exact-pair magnitude unestablished; protocol and comparator evidence are not completed co-use outcomes.
- Exact scope
- Oral melatonin with immediate-release trazodone; sleep-study and product formulations are not interchangeable. with Exact oral trazodone hydrochloride immediate-release tablets. RxNorm IN 10737/PIN 82112 hydrochloride; current immediate-release tablet scope. Oral solutions and modified-release products are not automatically equivalent.
- Medication form and route
- oral
- Timing or duration
- Source-specific single-dose, repeated-dose and observational exposures distinguished.
What remains uncertain
- Current captured protocol has no outcome data and inconsistent recruitment dates. Other-drug functional effects are indirect.
Factors that may matter: preparation and plant part; clinical indication; dose; other medicines; baseline alertness.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral trazodone.
Exact label names tryptophan and St John’s wort in serotonin warnings; strong CYP3A4 modifiers may change exposure. Drowsiness, orthostatic effects and QT warnings are distinct.
How this applies: RxNorm IN 10737/PIN 82112 hydrochloride; current immediate-release tablet scope. Oral solutions and modified-release products are not automatically equivalent.
No universal supplement interval, event rate or preparation equivalence established. Original label distinguishes warnings from measured pair-specific results.
Source 2: original trial protocol
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Planned forty-eight adults with moderate to severe traumatic brain injury and insomnia.
Protocol specifies daytime sleepiness and adverse-event monitoring; no completed outcome results are reported.
How this applies: Only the named drug, preparation, route and measured endpoints apply.
Protocol is not efficacy or safety evidence. Internal recruitment dates are inconsistent; current completion cannot be inferred.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 112 Parkinson disease patients randomized, 93 completing the trial.
Sleep quality improved in all groups; comparison tested alternatives.
How this applies: Only the named drug, preparation, route and measured endpoints apply.
No combination arm. Comparing adverse effects cannot establish concurrent melatonin-trazodone safety.
Source 4: official product label
medicines.org.uk · Source check Sep 10, 2026
Population: Participants in original interaction studies summarized by label.
No clinically significant pharmacokinetic interaction; greater tranquility and difficulty performing tasks compared with imipramine alone.
How this applies: Indirect imipramine co-use evidence only; no measured trazodone interaction in this product-label summary.
Label summary lacks full trial detail. Imipramine findings cannot establish desipramine, nortriptyline or trazodone interaction magnitude.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current exact available claims adjudicated using original captures and explicit identity and comparator limits. | |
| Research summary published |
Article revision: 4e536134b9650eb7
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.